Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6126041 | Transplant Immunology | 2013 | 35 Pages |
Abstract
The possible mechanism through which IL-35 and decitabine treatment increased the survival of graft tissues is to enhance the proliferation of CD4+CD25+ Treg cells and suppress the generation and function of effector T cells. Thus, IL-35 gene therapy combined with decitabine provides a novel approach to induce transplantation tolerance.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hao Guo, Wei Wang, Na Zhao, Xianghui He, Liwei Zhu, Xueming Jiang,